Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P15088 (mast cell)
 14,925 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Nasal turbinates were studied from 14 rhinitis patients following surgical turbinectomy, and from five subjects at autopsy. Mast cell counts on turbinectomy specimens were compared following staining with toluidine blue or Alcian blue and safranin after fixation in either paraformaldehyde or neutral buffered formalin. Mast cell numbers were significantly greater in the superficial submucosa than in the epithelium or deep submucosa in both the rhinitis group and the autopsy subjects. The combination of PFA fixation and ABS staining gave maximum mast cell counts, revealed two morphological mast cell sub-types and gave optimal demonstration of nasal tissue. Nasal mast cells are thus not uniformly distributed, appear heterogeneous under light microscopy, are present in large numbers even in the elderly, and are best demonstrated using PFA fixation and ABS staining.
 ...
PMID:A comparison of methods for nasal mast cell demonstration. 169 18

Mastocytosis is characterized by a clonal mast cell proliferation with organ infiltration and uncontrolled degranulation. Although not characteristic and poorly explained, some patients develop clotting abnormalities. We retrospectively identified patients with established diagnosis of mastocytosis and related clotting abnormalities (clinical and/or biological) using the national French Reference Centre for Mastocytosis database. From our cohort of 14 adult patients with clotting abnormalities (median age 46 years [range 26-75]), 4 had a presentation suggestive of a primary hemostasis disorder alone (by their symptoms and/or abnormal clotting tests [PFA, von Willebrand's disease [vWD] screening]) and 10 had a laboratory impairment of secondary hemostasis. Among these, 7 had bleeds characteristic of a coagulation cascade disorder (severe/life-threatening in 5 and mild in 2 patients). Clotting abnormalities were of variable severity, typically related to intense crisis of degranulation, such as anaphylactic reactions, and/or to severe organ infiltration by mast cells. Importantly, classical hemostatic management with platelet transfusion, fresh frozen plasma, or vitamin K infusions was unsuccessful, as opposed to the use of agents inhibiting mast cell activity, particularly steroids. This illustrates the crucial role of mast cell mediators such as tryptase and heparin, which interfere both with primary (mainly via inhibition of von Willebrand factor) and secondary hemostasis. There was interestingly an unusually high number of aggressive mastocytosis (particularly mast cell leukemia) and increased mortality in the group with secondary hemostasis disorders (n = 5, 36% of the whole cohort). Mast cell degranulation and/or high tumoral burden induce both specific biologic antiaggregant and anticoagulant states with a wide clinical spectrum ranging from asymptomatic to life-threatening bleeds. Hemostatic control is achieved by mast cell inhibitors such as steroids.
 ...
PMID:A French National Survey on Clotting Disorders in Mastocytosis. 2644 96